Table 1.
Clinicopathologic Features of 65 Patients Who Underwent at Least the First Stage of Two-Stage Resection and 62 Patients Treated by Chemotherapy Only
| Feature | Two-Stage Resection Strategy (n = 65) |
Chemotherapy Only(n = 62) |
P | ||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age, years | N/S | ||||
| Mean ± SD | 52 ± 9 | 55 ± 9 | |||
| Median | 52 | 54 | |||
| Range | 35-69 | 32-68 | |||
| Sex | N/S | ||||
| Male | 47 | 37 | |||
| Female | 18 | 25 | |||
| Rectal primary tumor | 18 | 28 | 11 | 18 | N/S |
| Node positive | 47 | 72 | 43 | 69 | N/S |
| Synchronous liver metastases | 52 | 80 | 52 | 84 | N/S |
| No. of lesions | N/S | ||||
| Mean ± SD | 6.7 ± 3.4 | 5.9 ± 2.9 | |||
| Median | 6 | 5.5 | |||
| Range | 2-18 | 2-14 | |||
| Tumor size, cm | N/S | ||||
| Mean ± SD | 4.5 ± 3.1 | 5.4 ± 3.4 | |||
| Median | 4 | 4 | |||
| Range | 1-15 | 1-17 | |||
| First-line chemotherapy regimen | |||||
| Fluorouracil + oxaliplatin | 46 | 71 | 41 | 66 | N/S |
| Fluorouracil + irinotecan | 19 | 29 | 21 | 34 | N/S |
| Bevacizumab-containing regimen | 48 | 74 | 38 | 61 | N/S |
| Multiple lines of preoperative chemotherapy | 6 | 9 | — | — | |
| No. of cycles of preoperative chemotherapy | — | — | |||
| Mean ± SD | 8 ± 5.6 | ||||
| Median | 6 | ||||
| Range | 2-26 | ||||
| CEA plasma level, ng/mL (preoperative or after initial response) | N/S | ||||
| Mean ± SD | 397 ± 2,232 | 255 ± 1,254 | |||
| Median | 6 | 13 | |||
| Range | 1-17,000 | 1-9,740 | |||
| Radiologic response using RECIST | |||||
| Partial or complete response | 28 | 62 | < .001 | ||
| Stable disease | 37 | 0 | |||
| Portal vein embolization | 45 | 70 | — | — | |
Abbreviations: N/S, not significant; SD, standard deviation; CEA, carcinoembryonic antigen; RECIST, Response Evaluation Criteria in Solid Tumors.